China's pharmaceutical market is growing at a scorching pace. Today China is one of the world’s largest pharmaceutical markets in the world. In 2011, China overtook Germany to become the world’s third largest pharmaceutical market behind Japan with sales of approximately $52.3 billion. With its volume and 20 per cent annual growth projection, China is set to become the world’s second largest pharmaceutical market by 2015.
China has increasingly become a focal point of the pharma world. Fuelled by increasing healthcare demands within its own borders as well as by international companies looking for manufacturing facilities, China's hunger for foreign partnerships and high-quality pharmaceutical ingredients presents great opportunities to international suppliers.
International pharma companies are constantly expanding their presence in China, investing large amounts in their own locations and relocating their R&D activities to the Middle Kingdom.
The Chinese market is attractive for them because of its ageing population, chronic disease growth, expanding healthcare insurance coverage, urbanization and increased investment in rural healthcare services.
In this context CPhI China, dedicated exhibition for the medical & pharmaceutical industry being held from June 26 to 28 at the SNIEC in Shanghai provides a direct view of the newest market trends and opportunities in China to the global pharma fraternity. CPhI China and ICSE China for contract and outsourced services, will be co-located with BioPh China for the biopharmaceutical sector, InnoPack China for innovative packaging services and solutions and LABWorld China for laboratory and analytical equipment needs .
The combined events are expected to host more than 27,000 attendees and 1,700 diverse exhibitors.
Exhibitors will get an opportunity to meet with key decision makers in pharmaceutical industry from 102 countries including China, India, US, UK, France, Italy etc.
CPhI China will feature new zones for general ingredients, APIs, intermediates, fine chemicals, and natural extracts. ICSE China will be split between contract services and outsourcing, while BioPh China will remain dedicated to biopharmaceuticals only. Co-located event, P-MEC China, will feature a general zone, as well as one for machinery and equipment and one for environment protection and clean technology.
The event will display many products like chemical reacting equipment, drying equipment, crystalling equipment, distillation equipment, screening machine, sterilizing equipment, filter press equipment and many more
"The size and synergies of CPhI China, ICSE China and the co-located events create a dedicated marketplace for companies to find products and services, including standard and custom APIs. In the Asian pharma market, an increased emphasis has been placed on producing high quality drugs faster as many blockbuster drug patents expire. There is a large interest in generics and biosimilars, as the market demands better versions of drugs at a cheaper price. Statistics have shown that the Chinese market could double as the country improves its health care systems and regulations and IMS Health projected that drug revenue in China would grow by $40 billion through 2013," UBM Brand Director, Haf Cennydd said
"APIs make up more than 50 per cent of the export value of China’s pharmaceutical trade and is it estimated that the Chinese market for APIs will witness a compound growth rate of 18 per cent from 2010 to 2017. In this flourishing environment CPhI China, ICSE China and co-located events are the only events of their kind that can offer direct access to so many sectors of the Chinese pharmaceutical industry."
China has the low cost labour and state-of-the art-plants. The country’s solid pharmaceutical manufacturing prowess together with the machinery design and production development can be capitalized by the developed world to produce affordable drugs under supervision by the sourcing company.
According to a section of the international industry observers, for the People’s Republic of China, the effort is to increase its API exports and grab orders for contract manufacturing from the event. It is also scouting to increase the foreign direct investments for formulation development and collaborate for research which will provide the country a global footprint.
Specifically for formulations and research, China is addressing the economies- of-scale for manufacture backed by its strong API capability. It also intends to expand its portfolio in pharmaceuticals with brand development instead of solely focusing as a raw material supplier. In the case of research, it needs new molecules and this is where hand-holding with global majors is being considered as a relevant and easy to faster growth.
CPhI China 2012 will have a zone-based layout for the first time in its history. Successfully introduced at the CPhI Worldwide events, the new zoning format aims to increase visitor ROI while on-site and supports the goal of more time spent meeting with colleagues and less time spent navigating the exhibition halls.
Exhibitors are located into different zones based on the pharamceutical ingredients or services they provide. Within the events, there are zones targeted towards specific products and services which will make contacts easier to find the first time. CPhI China will feature new zones for general ingredients, APIs, intermediates, fine chemicals, and natural extracts. ICSE China will be split between contract services and outsourcing, while BioPh China will remain dedicated to biopharmaceuticals only. Co-located event, P-MEC China, will feature a general zone, as well as one for machinery and equipment and one for environment protection and clean technology.
A modular conference programme featuring six bookable sessions will highlight the drivers of the current economy and how to navigate the market as it changes. The specific module topics include pharmaceutical manufacturing, commercializing R&D, export strategies and regulations, developing biosimilars, API sourcing, and delivering re-innovated generics.
The modules will be structured over day one and day two, and will be presented by high level speakers from the FDA in China, and leading multi-nationals including Pfizer, Boehringer-Ingelheim, Novartis, and GSK China.
The recent 12 th edition of China's Five-year Plan (for years 2011 to 2015) will also help to serve as a guide for companies to strengthen the national drug distribution industry through active support of acquisitions, mergers and reorganizations, as well as the formulation of competitive strategies for the future. The combined China pharma events provide visitors with a unique opportunity to network directly with key decision makers in the Asian pharmaceutical industry through both existing and new contacts.
CPhI China, ICSE China and co-located shows provide a one stop location for sourcing quality pharmaceutical products and services at a reasonable price. The event will provide unrivalled access to the pharmaceutical industry from which to launch new products and increase market knowledge, meet with other key decision-makers who are searching for business opportunities, partnership, new products and services.
According to an Espicom study , the Chinese pharmaceutical market will grow by a moderate double-digit figure between 2012 and 2017. China will be the largest pharmaceutical market in the Asia Pacific region, overtaking Japan in 2016 and will represent over a third of the Asia Pacific region’s total pharmaceutical market in 2017.